Pablo Mando, Editor-in-Chief of Oncologia Clínica, shared a post on X:
“Great presentation by Carlos Barrios reporting that T-DXd demonstrated a clinically meaningful efficacy benefit over both TPC subgroups (capecitabine and taxane), with improved PFS, ORR, DOR, and PFS2 in DB-06.”
Paolo Tarantino, Advanced Research Fellowship at Dana-Farber Cancer Institute and Harvard Medical School, reshared the post on X, adding:
“Seems to confirm a frequent empirical finding:
capecitabine > taxanes for treating HR+/HER2- MBC (with T-DXd outperforming both).”
More posts featuring Paolo Tarantino.